Search
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalUmeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath,...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesStiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigationalStiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. The clinical development and marketing of stiripentol were first delayed due to the drug's...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsTechnetium Tc-99m sestamibi
go.drugbank.com/drugs/DB09161ApprovedInvestigationalTechnetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) l...
Categories: P-glycoprotein substratesLobeglitazone
go.drugbank.com/drugs/DB09198InvestigationalLobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. B...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsCiglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones....
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedTolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment fo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBlonanserin
go.drugbank.com/drugs/DB09223InvestigationalBlonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMelperone
go.drugbank.com/drugs/DB09224InvestigationalMelperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It h...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCilnidipine
go.drugbank.com/drugs/DB09232InvestigationalCilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEfonidipine
go.drugbank.com/drugs/DB09235InvestigationalEfonidipine is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors